Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine

Cephalalgia. 1989:9 Suppl 9:79-82. doi: 10.1111/J.1468-2982.1989.TB00077.X.

Abstract

Subcutaneous GR43175 was examined in patients with acute migraine for efficacy, tolerability and safety in an open, controlled, dose-ranging study. Ten patients with acute, non-medicated, migraine (15 attacks) were assessed for severity of headache and associated symptoms (nausea, vomiting and photophobia). GR43175 plasma samples were monitored serially after dosing. Doses of 2 mg or 3 mg gave rapid relief of all migraine symptoms. Thirteen attacks (86%) had either resolved completely or improved to a mild non-migraine residual headache within 40 min. Treatment was well tolerated at all doses, the only adverse effects being transient pain on injection. Peak plasma concentrations were obtained within 10-20 min; a decline in plasma drug concentration did not result in a relapse in headache severity.

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indoles / administration & dosage
  • Indoles / pharmacokinetics
  • Indoles / therapeutic use*
  • Injections, Subcutaneous
  • Male
  • Migraine Disorders / drug therapy*
  • Nausea / chemically induced
  • Sulfonamides / administration & dosage
  • Sulfonamides / pharmacokinetics
  • Sulfonamides / therapeutic use*
  • Sumatriptan

Substances

  • Indoles
  • Sulfonamides
  • Sumatriptan